v ::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::
ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

A STUDY ON QUALITY OF LIFE AND DRUG UTILIZATION PATTERN IN PATIENTS WITH MYOCARDIAL INFARCTION

AUTHORS:

C Rozamliana, Jomon MK, Sharon Merin Baboo, Stefin Jose K, Apoorva Dev*

ABSTRACT:

Back ground: Myocardial infarction is a key component of the burden of cardiovascular disease. The physical and psycho emotional impact caused by the disease has contributed to the impairment of quality of life of patients in medium and long term. Objectives: The objective of study is to assess the quality of life and drug utilization pattern in patients with myocardial infarction. Methodology: The present study is a prospective observational study. The study included 120 patients which included assessment of quality of life and prescribing pattern from WHOQOL questionnaire and medical records respectively. Results: Out of 120 patients, male [80.83%] were predominantly affected over female [19.16%] with major risk factors diabetes mellitus [45.83%] and HTN [43.33%]. MI was mostly prevalent in the age group 40-60 years [45.83%] and 60-80 years [49.16%]. The initial QOL scores among four domains physical [14.08 ± 2.33], psychological [13.05 ± 3.11], social [6.42 ± 1.84] and environment [13.98 ± 4.67] has significantly improved during the follow up to physical [25.36±3.69], psychological [23.77±2.88], social [11.78±1.85] and environment [28.58±3.57] respectively. Anti-platelets [199.16%], lipid lowering agents [90%], beta-blockers [51.66%] and vasodilators [43.33%] were most commonly prescribed class of drug in Myocardial Infarction (MI) patients. Conclusion: The present study signifies the improvement in the quality of life by proper medication adherence and lifestyle followed. The most commonly prescribed class of drugs were anti-platelets and lipid lowering agents in MI patients. Key words: Myocardial infarction, quality of life, drug utilization pattern.

FULL TEXT

Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.